108
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Budget Impact Analysis of Switching to Rituximab’s Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa

Pages 527-534 | Published online: 15 Sep 2020

Figures & data

Table 1 Dosing Regimens of Rituximab in All Approved Indications

Figure 1 The estimation model and weights for the budget impact analysis study. Weightings were calculated according to the following formula: where j is the incidence rate of indication j. consumption per year j is the total need of milligrams for the treatment of indication j. rituximab treatment rate is the proportion of patients treated in indication j treated with rituximab.

Abbreviations: RA, rheumatoid arthritis; NHL, Non-Hodgkin’s lymphoma; CLL, chronic lymphocytic leukemia.
Figure 1 The estimation model and weights for the budget impact analysis study. Weightings were calculated according to the following formula: where j is the incidence rate of indication j. consumption per year j is the total need of milligrams for the treatment of indication j. rituximab treatment rate is the proportion of patients treated in indication j treated with rituximab.

Table 2 A Projection of Total Budget Impact Savings Related to the Introduction of a Rituximab Biosimilar Over a 1-Year Period in Addition to the Number of Patients That Would Benefit from Gaining Accessibility to Rituximab Treatment